Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
TSI EDITOR |
2021-04-16
Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
TSI EDITOR |
2021-04-15
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
TSI EDITOR |
2021-04-15
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships
TSI EDITOR |
2021-04-14
A recent study shows HALF of all adults already experiencing anxiety due to the social isolation from COVID-19 lockdowns. COVID Isolation Syndrome.
TSI EDITOR |
2021-04-14
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
TSI EDITOR |
2021-04-13
Mydecine commences screening psilocybin-based drug candidates.
TSI EDITOR |
2021-04-13
Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.
TSI EDITOR |
2021-04-13
Utilizing Speak Ai’s technology, iSTRYM will provide-AI-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
TSI EDITOR |
2021-04-13
Forty years ago, cannabis was labelled "a Gateway Drug" to harder drug use -- such as psychedelics. Today, cannabis is the Gateway Drug to psychedelics legalization.
TSI EDITOR |
2021-04-12
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now